Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

642
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
642
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

34
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
34
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

488
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
488
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Serendipity to Science: How Anti-HMGCR Antibodies Changed Our Understanding of Myositis.

The Journal of rheumatology·2026
Same author

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

ACR open rheumatology·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Nature communications·2026
Same author

Clinical characteristics and risk factors associated with objective flares in patients with dermatomyositis.

Seminars in arthritis and rheumatism·2026
Same author

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Clinical and experimental rheumatology·2026

Related Experiment Video

Updated: Apr 24, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

13.4K

Inclusion body myositis: update.

Arash H Lahouti1, Anthony A Amato, Lisa Christopher-Stine

  • 1aDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Current Opinion in Rheumatology
|September 13, 2014
PubMed
Summary
This summary is machine-generated.

Recent advancements in sporadic inclusion body myositis (IBM) offer new diagnostic criteria and potential treatments. This review explores updated clinical factors, autoantibodies, and histopathology for improved understanding and management of IBM.

More Related Videos

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
09:17

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Published on: August 24, 2017

7.6K

Related Experiment Videos

Last Updated: Apr 24, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

13.4K
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
09:17

Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

Published on: August 24, 2017

7.6K

Area of Science:

  • Neurology
  • Immunology
  • Pathology

Background:

  • Sporadic inclusion body myositis (IBM) is a slowly progressive inflammatory myopathy.
  • Understanding its clinical, prognostic, and pathological features is crucial for patient care.

Purpose of the Study:

  • To review recent developments in sporadic inclusion body myositis (IBM).
  • To cover updated clinical and prognostic factors, novel autoantibody associations, histopathologic findings, diagnostic criteria, and therapeutic agents.

Main Methods:

  • Literature review of recent studies on sporadic inclusion body myositis (IBM).

Main Results:

  • IBM progression varies, with wheelchair dependence typically occurring 12-20 years post-symptom onset, without impacting life expectancy.
  • Older age at onset and immunosuppressive therapy correlate with faster disease progression.
  • Quantitative muscle strength and functional rating scales serve as effective outcome measures for clinical trials.
  • New data-driven diagnostic criteria demonstrate high sensitivity and specificity.
  • Novel autoantibodies and unique histopathologic proteins aid in diagnosis and understanding pathophysiology.
  • Emerging treatments like follistatin and bimagrumab target specific pathways.

Conclusions:

  • Recent research has significantly expanded the knowledge of IBM, challenging previous understanding.
  • These advancements herald a new era in IBM research with potential clinical benefits for patients.